ALNY
Alnylam Pharmaceuticals, Inc.
Stock
$219.72−11.46 (−4.96%)Close Oct 2, 2026
- Capital expenditures, 2025
- $59M
- YoY, 2025
- +71.2%
- 5-year CAGR
- −3.6%
- 10-year CAGR
- +16.3%
Capital expenditures
Capital expenditures by fiscal year
| Period | Capex | YoY |
|---|---|---|
| 2025 | $59M | +71.2% |
| 2024 | $34M | −44.9% |
| 2023 | $62M | −13.7% |
| 2022 | $72M | −5.6% |
| 2021 | $76M | +8.5% |
| 2020 | $70M | −49.8% |
| 2019 | $140M | +10.5% |
| 2018 | $127M | +21.8% |
| 2017 | $104M | +61.4% |
| 2016 | $65M | +398.5% |
| 2015 | $13M | +44.5% |
| 2014 | $9.0M | +123.7% |
| 2013 | $4.0M | −52.0% |
| 2012 | $8.3M | +546.6% |
| 2011 | $1.3M | −72.7% |
| 2010 | $4.7M | −4.4% |
| 2009 | $4.9M | −54.0% |
| 2008 | $11M | — |